Rational development of peptide vaccination in clinical oncology

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

European journal of cancer (Oxford, England : 1990)·2024

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.

European journal of cancer (Oxford, England : 1990)·2023

Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

Onkologie·2013

Metastatic germ cell tumour following renal transplantation.

Onkologie·2013

miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

Onkologie·2013

A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

Onkologie·2013

Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

Onkologie·2013

Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

Onkologie·2013

Cannabis Use by Veterans and Potential Interactions With Antineoplastic Agents: Analysis and Literature Review.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2026

Combined treatment of benznidazole with an electrolyzed oxidizing water against Trypanosoma cruzi on immunological and anatomopathological features in a murine model of Chagas disease.

Frontiers in immunology·2026

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant Enterobacterales Bacteremia in Patients With Hematologic Malignancies.

Journal of Korean medical science·2026

When CO2 sensing fails: Protective effects of sex hormones and potential mechanisms.

Journal of neuroendocrinology·2026

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials.

World journal of gastrointestinal pharmacology and therapeutics·2026

[Oral urea in paraneoplastic syndrome of inadequate antidiuretic hormone secretion due to small-cell carcinoma ‒ Sustained, safe, and cost-effective correction through outpatient management].

Nutricion hospitalaria·2026

Related Experiment Videos

Rational development of peptide vaccination in clinical oncology

Related Concept Videos

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.

Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

Metastatic germ cell tumour following renal transplantation.

miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

Cannabis Use by Veterans and Potential Interactions With Antineoplastic Agents: Analysis and Literature Review.

Combined treatment of benznidazole with an electrolyzed oxidizing water against Trypanosoma cruzi on immunological and anatomopathological features in a murine model of Chagas disease.

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant Enterobacterales Bacteremia in Patients With Hematologic Malignancies.

When CO2 sensing fails: Protective effects of sex hormones and potential mechanisms.

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials.

[Oral urea in paraneoplastic syndrome of inadequate antidiuretic hormone secretion due to small-cell carcinoma ‒ Sustained, safe, and cost-effective correction through outpatient management].

Related Experiment Videos

Rational development of peptide vaccination in clinical oncology

Related Concept Videos

Related Articles